Prevalence Study of Gastrointestinal Risk Factors in Patients With Osteoarthritis (OA), Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS). (RATIONAL)

AstraZeneca

Status: Completed

Conditions: Ankylosing Spondylitis (AS); Rheumatoid Arthritis (RA); Osteoarthritis (OA)

Study type: Observational

Funder types: Industry

Identifiers

NCT01577563

NIS-PLA-XXX-2011/1

Details and patient eligibility

About

RATIONAL is a multinational, multicentre, observational, cross sectional study of adult patients in treatment with NSAID therapy for OA, RA or AS during for at least 2 weeks before study visit (at least one dose).

Full description

Prevalence study of gastrointestinal risk factors in patients with osteoarthritis, rheumatoid arthritis and ankylosing spondylitis receiving treatment with non- steroidal anti- inflammatory drugs.

Enrollment: 5,383 patients

Sex: All

Ages: 21+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Provision of subject informed consent.
• Female and/or male, aged > 21 years.
• Patients diagnosis with RA (ACR 1987 or ACR/EULAR 2010 criteria), OA (ACR 1986, 1990 and 1991 criteria) or AS (New York 1984 criteria or ESSG 2002 criteria) (documented in the medical record).
• Patients receiving at least one dose of NSAIDs.

Exclusion criteria

• Participation in any interventional study involving investigational drugs.
• Patient refuses to fill in the study questionnaires.
• Pregnant or breastfeeding women.
• Patients with active neoplastic disease in the last 5 years, except basal-cell carcinoma.